919P - Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

Andrea Necchi ,N.J Vozelgang,J.-L Lee,Daniel P Petrylak ,Lawrence Fong ,Yves Fradet ,James Luke Godwin ,David I Quinn ,Ronald De Wit ,Howard Gurney ,Miguel Ángel Climent ,Kijoeng Nam ,Toni K Choueiri ,Cora N Sternberg ,Winald R Gerritsen ,Dean F Bajorin ,Joaquim Bellmunt ,Stéphane Culine ,Tara L Frenkl ,David J Vaughn

doi:10.1093/annonc/mdz249.018

919P - Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

Andrea Necchi , N.J Vozelgang + Show 18 more

Open Access

https://doi.org/10.1093/annonc/mdz249.018

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 9	License type: publisher-specific-oa

#Research Grant #Funding Institution + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

919P - Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

Full Text